DPP4 and type 2 diabetes mellitus: Specifically, peptides were considered ADPs if their iDPPIV-SCM scores exceeded 300 and based on their predicted ability to inhibit dipeptidyl peptidase IV (DPP-IV) (PDB ID: 2ONC), a well-established therapeutic target for managing type 2 diabetes (Table 4).